RESUMO
To date, no accepted therapy exists for treating the emerging infectious disease nCOVID-19 in a safe and effective way. Although various treatment options are under in the developing phase around the world, several studies concerning convalescent plasma (CP) from recovered patients reported promising effects against nCOVID-19 infected critically ill patients nowadays. The therapy showed very few adverse effects, and it helps diminish the viral load when administered at an early stage of infection. Convalescent plasma appears safe for critically ill nCOVID-19 patients by decreasing serum viral loads, and most cases are virus negative after CP transfusion. The convalescent plasma can be good as it has already been utilized to treat previous pandemics like Ebola, influenza, and SARS-CoV infection. In this review article, we pointed out CP's background, rationality, mechanisms, and safety outcomes to treat nCOVID-19 infected patients.